TFF Pharmaceuticals, Inc.

TFFP

US87241J2033

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:34:50 2024-07-16 EDT			5-day change	1st Jan Change
2.005 ^USD	+0.75%		+4.71%	-71.51%

07-01	TFF Pharmaceuticals, Inc Announces Resignation of Michael Patane from its Board of Directors	CI
07-01	Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2024.	CI

TFF Pharmaceuticals, Inc Announces Resignation of Michael Patane from its Board of Directors

July 01, 2024 at 06:12 am

TFF Pharmaceuticals, Inc. announced that on June 26, 2024, Michael Patane tendered his resignation from its Board of Directors effective as of June 30, 2024.

Latest news about TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc Announces Resignation of Michael Patane from its Board of Directors	07-01	CI
Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2024.	06-30	CI
Certain Options of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2024.	06-30	CI
Certain Common Stock of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2024.	06-30	CI
Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection	06-24	CI
TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing	05-23	MT
TFF Pharmaceuticals, Inc. and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing	05-23	CI
TFF Pharmaceuticals Advances Influenza Vaccine Candidates Into Preclinical Testing	05-20	MT
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing	05-20	CI
Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection	05-15	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	04-30	MT
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	04-29	CI
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	04-15	CI
TFF Pharmaceuticals Files Equities Shelf	04-08	MT
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	03-28	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-28	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating	03-28	MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call	03-27
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	03-27	CI
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	03-20	MT
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	03-20	CI
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	01-24	CI
Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	12-30	CI

Chart TFF Pharmaceuticals, Inc.

Duration

Period

More charts

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for TFF Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.99 USD

Average target price

17 USD

Spread / Average Target

+754.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TFF PHARMACEUTICALS, INC.	-71.51%	6.17M
MODERNA, INC.	+24.46%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	-0.42%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+32.86%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.74%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.42%	14.52B
MEDPACE HOLDINGS, INC.	+47.43%	13.74B
BIO-TECHNE CORPORATION	+2.21%	12.17B

Other Biotechnology & Medical Research